Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

COX-1, COX-2: so what?

P Emery

    Scandinavian Journal of Rheumatology
    |March 26, 1999
    PubMed
    Summary
    This summary is machine-generated.

    The discovery of cyclooxygenase-2 (COX-2) has rapidly advanced science and medicine. This review covers new data from COX-2 inhibitor phase II studies and their implications.

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Repeatability of quantitative MRI in patients with rheumatoid arthritis.

    Radiography (London, England : 1995)·2022
    Same author

    Quantitative MRI in myositis patients: comparison with healthy volunteers and radiological visual assessment.

    Clinical radiology·2020
    Same author

    MRI in acute muscle tears in athletes: can quantitative T2 and DTI predict return to play better than visual assessment?

    European radiology·2020
    Same author

    Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis.

    Scandinavian journal of rheumatology·2020
    Same author

    Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison.

    RMD open·2020
    Same author

    Differential CpG DNA methylation in peripheral naïve CD4<sup>+</sup> T-cells in early rheumatoid arthritis patients.

    Clinical epigenetics·2020
    Same journal

    Multimodal imaging in the diagnosis of iliopsoas bursitis complicating biological therapy in rheumatoid arthritis: a case report with therapeutic implications.

    Scandinavian journal of rheumatology·2026
    Same journal

    Real-world clinical outcomes of patients with disproportionate articular pain in rheumatoid arthritis: ANSWER cohort study.

    Scandinavian journal of rheumatology·2026
    Same journal

    Cervical spine instability in axial spondyloarthritis: prevalence, patterns, and predictive factors in a high-risk cohort.

    Scandinavian journal of rheumatology·2026
    Same journal

    On the interpretation of validation in register-based identification of polymyalgia rheumatica.

    Scandinavian journal of rheumatology·2026
    Same journal

    Answer to: 'On the interpretation of validation in register-based identification of polymyalgia rheumatica' by Tanveer and Irfan.

    Scandinavian journal of rheumatology·2026
    Same journal

    Clinical and histopathological features of a population-based cohort of 95 consecutive patients with immunoglobulin G4-related disease in Stockholm, Sweden, during a five-year period.

    Scandinavian journal of rheumatology·2026
    See all related articles

    Area of Science:

    • Biochemistry
    • Pharmacology
    • Clinical Medicine

    Background:

    • The identification of the cyclooxygenase-2 (COX-2) enzyme isoform has spurred significant research.
    • This has led to the development of novel therapeutic strategies targeting inflammation and pain.

    Discussion:

    • Review of recent phase II clinical trial data for selective COX-2 inhibitors.
    • Analysis of the expanding body of basic science, pharmacological, and clinical information related to COX-2.

    Key Insights:

    • Selective COX-2 inhibition represents a promising therapeutic avenue.
    • Understanding COX-2's role is crucial for developing targeted anti-inflammatory drugs.

    Outlook:

    • Further clinical evaluation of COX-2 inhibitors is warranted.
    • Continued research into the biological functions and therapeutic potential of COX-2 is expected.